Company news
Lb Pharmaceuticals Inc (NASDAQ:LBRX) news
Lb Pharmaceuticals Inc news releases on 6ix. Latest, Oct 6, 2026: LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing…
Press releases & updates
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
October 5, 2026
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
October 6, 2026
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer
September 15, 2026
LB Pharmaceuticals to Participate in Upcoming September Investor Events
September 3, 2026
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
September 3, 2026
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026
LB Pharmaceuticals Announces $150 Million Private Placement
July 29, 2026
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia
July 22, 2026
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
June 30, 2026
LB Pharmaceuticals to Participate in Upcoming June Investor Events
May 28, 2026
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 12, 2026
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
April 22, 2026
LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
March 26, 2026
LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 25, 2026
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
March 24, 2026
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
March 8, 2026
LB Pharmaceuticals to Participate in Upcoming March Investor Events
March 3, 2026
LB Pharmaceuticals Announces $100.0 Million Private Placement
February 5, 2026
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program
January 26, 2026
LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel
January 21, 2026
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2026
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture
January 6, 2026
LB Pharmaceuticals Added to the Russell 2000 and Russell 3000 Indices
December 10, 2025
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices
December 9, 2025
LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference
November 24, 2025
LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer
November 12, 2025
LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference
November 6, 2025
LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates
November 6, 2025
LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs
October 14, 2025
LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms
October 6, 2025
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani
September 25, 2025
LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering
September 9, 2025